PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia
Launched by M.D. ANDERSON CANCER CENTER · Mar 11, 2015
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring new ways to detect a type of cancer called extramedullary myeloid leukemia in patients who have just been diagnosed with acute myeloid leukemia (AML). Extramedullary myeloid leukemia occurs when cancer cells spread outside the bone marrow, and it can be challenging to find using standard tests. The study will use advanced imaging techniques, such as PET/MRI, 18F-FDG PET/CT, and whole-body MRI, to see if these methods can help identify this type of leukemia more effectively.
To participate in the trial, you need to be an adult aged 18 or older who has recently been diagnosed with AML. The study is open to people who speak different languages, as translation services will be provided. However, there are some conditions that would exclude you from participating, such as certain medical issues, previous treatments for leukemia, or if you are pregnant. If you join the study, you can expect to undergo various imaging tests, and the goal is to find better ways to diagnose and manage this type of leukemia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with newly diagnosed AML
- • Non-English speaking subjects will be included. Verbal Translation Preparative Sheet (VTPS) short form will be utilized in consenting non-English speaking subjects.
- Exclusion Criteria:
- • Patients with contraindications to MR
- • Patients with a known allergy to MR contrast agents
- • Uncontrollable claustrophobia
- • Recipients of more than minimal anti-leukemia treatment, with minimal treatment defined as: leukapheresis, hydroxyurea, or Cytarabine more than 1 g per square meter.
- • Patients with secondary or relapsed AML or APL should be excluded.
- • Patients with known extramedullary leukemia
- • Positive pregnancy test in a female of childbearing potential
- • Younger than 18 years
- • Greater than 400 pounds in weight
- • Patients with uncontrolled diabetes
- • Cognitive impaired adults or prisoners will be excluded
- • Estimated glomerular filtration rate (eGFR \<30) will be excluded
About M.D. Anderson Cancer Center
The University of Texas MD Anderson Cancer Center is a leading institution dedicated to cancer care, research, education, and prevention. As one of the world’s most respected cancer centers, MD Anderson focuses on innovative treatment approaches and groundbreaking clinical trials aimed at improving patient outcomes. With a multidisciplinary team of experts and state-of-the-art facilities, the center is committed to advancing cancer research and providing comprehensive, personalized care to patients. MD Anderson's clinical trials play a pivotal role in translating scientific discoveries into effective therapies, positioning the center at the forefront of cancer treatment and research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Houston, Texas, United States
Patients applied
Trial Officials
Dawid Schellingerhout
Principal Investigator
M.D. Anderson Cancer Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials